Company: MDCXW
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001062993-25-007073
Chunk: 127

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-04
Form: POS AM
Chunk 127
---
 |
| William L. Ashton(2) (3) (4) (5) |     |  74 |     | Director                                       |
| Barry Fishman(4) (5)             |     |  67 |     | Director                                       |
| Dr. Sara R. May(2)               |     |  47 |     | Director                                       |
| Dr. Raza Bokhari(3)              |     |  58 |     | Executive Chairman and Chief Executive Officer |
| Carolyn Bonner                   |     |  41 |     | President                                      |
| James Quinlan                    |     |  61 |     | Chief Financial Officer                        |
| Dr. Edward Brennan               |     |  65 |     | Chief Scientific Officer & Head of R&D Program |
| Dr. Faisal Mehmud                |     |  50 |     | Chief Medical Officer                          |

Notes:

(1)Member of the Compensation Committee. Mr. Lavelle is the Chair.

(2)Member of the Audit Committee. Mr. Ciaruffoli is the Chair.

(3)Member of the Corporate Disclosure Committee. Mr. Ciaruffoli is the Chair.

(4)Member of the Governance Committee. Mr. Fishman is the Chair.

(5)Member of the Nominating Committee. Dr. Kaiser is the Chair.

Set forth below is a description of the background of the directors and executive officers of Medicus.

Dr. Raza Bokhari, Executive Chairman and Chief Executive Officer

Dr. Bokhari has served as our Executive Chairman and Chief Executive Officer since September 2023. Dr. Bokhari works full time for the Company.

A recipient of Philadelphia Business Journal's "40 under 40" award, Dr. Raza Bokhari, a physician turned serial entrepreneur, has a demonstrated successful track record in aggregating and accelerating life sciences, healthcare services and Pharmaceutical R&D companies.

He previously served as Executive Chairman and CEO of FSD Pharma (Nasdaq: HUGE) (2020 to 2021), where his strategies successfully pivoted the company out of medicinal cannabis and into a clinical stage pharmaceutical R&D, a transition marked by a NASDAQ listing in January 2020, and raising nearly $100M institutional capital to fuel growth and expansion.

<div align='center'>-90-</div>

In addition to his corporate roles, Dr. Bokhari serves as the Vice Chairman of the World Affairs Council of Philadelphia.